Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SCLC-State of the Art and What Does the Future Have in Store?

Clinical lung cancer - 1 Sept 2016

Kahnert Kathrin, Kauffmann-Guerrero Diego, Huber Rudolf Maria

Abstract excerpt

Worldwide, the total number of diagnosed lung cancer cases amounts to 1.8 million every year. Small-cell lung cancer (SCLC) accounts for about 15% to 17% of all diagnosed lung cancers. Despite all progress made in the field of non-small-cell lung cancer, the prognosis and therapeutic options in SCLC are still limited. The resistance of SCLC to conventional therapy as well as its high recurrence rate can be...

Topics

Join the communities discussing this publication.

Drug Design
Drug Resistance, Neoplasm
Immunotherapy
Lung Neoplasms
Molecular Targeted Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Recurrence, Local

Small Cell Lung Carcinoma

Source

Identifiers

PMID: 27397481
DOI: 10.1016/j.cllc.2016.05.014

Genes

FGFR1
JAK2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SCLC-State of the Art and What Does the Future Have in Store?PMID 27397481Read ↗

Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilitiesSemantic proximity Read ↗

The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.Semantic proximity Read ↗

Molecular subtyping of small cell lung cancer.Semantic proximity Read ↗

Origins, genetic landscape, and emerging therapies of small cell lung cancer.Semantic proximity Read ↗

The molecular pathogenesis of small cell lung cancerSemantic proximity Read ↗

Targeted therapies for small cell lung cancer: Where do we stand?Semantic proximity Read ↗

Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potentialSemantic proximity Read ↗

Small Cell Lung Cancer: State of the Art of the Molecular and Genetic Landscape and Novel PerspectiveSemantic proximity Read ↗

SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection.Semantic proximity Read ↗

Lung Cancer: Are we up to the Challenge?Semantic proximity Read ↗

Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies.Semantic proximity Read ↗

Lung cancer: Biology and treatment options.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.